Results 141 to 150 of about 2,147 (178)

Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis

Cardiology in Review, 2022
Pericarditis is the commonest form of pericardial disease. Unfortunately, despite optimal treatment, approximately 15–30% of patients with acute pericarditis have recurrence. Many of these patients are refractory to colchicine, and become corticosteroid-dependent.
Akshay, Goel, Dhrubajyoti, Bandyopadhyay, Aaqib H, Malik, Rahul, Gupta, William H, Frishman, Wilbert S, Aronow   +5 more
core   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)

Expert Opinion on Biological Therapy, 2009
Cryopyrin-associated periodic syndromes (CAPS) encompass a group of rare inherited, autoinflammatory disorders that represent a spectrum of one disease with varying degrees of severity. Until recently, there was no effective treatment for CAPS, but identification of the genetic basis of CAPS highlighted the pathogenic role of IL-1beta.Rilonacept is a ...
Hal Hoffman
exaly   +3 more sources

Rilonacept

Drugs of the Future, 2007
null Sorbera, L.A., null Bozzo, J., null Bayes, M.   +2 more
openaire   +2 more sources

Rilonacept

Nature Reviews Drug Discovery, 2008
Hal M. Hoffman, Uma Yasothan, Peter Kirkpatrick   +2 more
openaire   +2 more sources

Rilonacept use in lupus pericarditis

Clinical and Experimental Rheumatology, 2023
Lupus pericarditis affects 22% of patients with systemic lupus erythematosus (SLE), is associated with worse outcomes, and often requires immunosuppression. Rilonacept is an interleukin-1 receptor antagonist approved for the treatment of recurrent idiopathic pericarditis, but its efficacy in lupus pericarditis is unknown.
Andrea, Fava, Michael, Cammarata, Luigi, Adamo   +2 more
openaire   +2 more sources

Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study [PDF]

Clinical Therapeutics, 2012
BackgroundCryopyrin-associated periodic syndromes (CAPS) are rare, inherited autoinflammatory disorders associated with considerable hardship to patients.
Hal Hoffman, Alan Kivitz
exaly   +2 more sources

Ciclosporin/prednisone/rilonacept

Reactions Weekly, 2018
openaire   +2 more sources

Rilonacept

, 2013
Giuseppe Tridente
openaire   +2 more sources

New Indication for Rilonacept

AJN, American Journal of Nursing, 2021
Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older. The drug is given subcutaneously.
openaire   +1 more source

Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis

Annals of Pharmacotherapy, 2021
Objective To review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP). Data Sources A MEDLINE search was conducted between January 2006 and April 2021 using the ...
openaire   +2 more sources